All In Biotech

NDA 205912 · Praxair Distribution INC

Helium, Usp

Helium · Inhalation

Last checked: Nov 20, 2026Latest source record: Aug 5, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Aug 5, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

39

4 Phase 3, 0 recruiting

FAERS reports

50

46 serious, 33 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 15, 2025.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 5, 2013 Original approval · Medical Gas Letter
1 products under this application
  • HELIUM, USP · HELIUM N/A · GAS, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Helium" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • completed suicide23
  • asphyxia6
  • overdose6
  • toxicity to various agents5
  • generalised tonic-clonic seizure4
  • sedation4
  • drug level increased3
  • myalgia3
  • off label use3
  • abnormal behaviour2
  • aggression2
  • cataplexy2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20071
20133
20147
20159
20163
201711
20182
20198
20201
20212
20221
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 296 on PubMed

Sponsor: Praxair Distribution INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.